Jonathan White, PA
Medical · Seattle, WANPI 1093163123
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,921 of the $13,144 with a category attached, or 67.9%. 28 manufacturers reported payments, led by Gilead at 53.7% of the total. 2025 is the largest year on record at $6,810, 5.1 times the $1,331 reported in 2021. Among medical clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $37.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$7K
- Viiv Healthcare Company$3K
- EMD Serono, Inc.$752
- Johnson & Johnson$484
- Pfizer$329
- Novo Nordisk$252
- plus $2K from 22 others
What the payments were for
- Consulting fees$3,19024%
- Travel & lodging$1,0048%
- Food & beverage$8,92168%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 86 | $7,055 |
| Viiv Healthcare Company | 111 | $2,581 |
| EMD Serono, Inc. | 28 | $752 |
| Johnson & Johnson(2 entities) | 21 | $484 |
| Pfizer | 15 | $329 |
| Novo Nordisk | 11 | $252 |
| Antares Pharma, Inc. | 17 | $242 |
| Merck | 8 | $180 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $175 |
| AbbVie | 6 | $144 |
| GSK | 1 | $117 |
| Idorsia Pharmaceuticals US Inc | 6 | $110 |
| Lilly USA, LLC | 4 | $102 |
| Napo Pharmaceuticals Inc | 4 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Janssen Scientific Affairs, LLC | 3 | $67 |
| Clarus Therapeutics Inc. | 3 | $62 |
| Exact Sciences | 2 | $53 |
| Hologic Sales And Service, LLC | 2 | $42 |
| Collegium Pharmaceutical, Inc. | 2 | $39 |
| Endo Pharmaceuticals Inc. | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $33 |
| Theratechnologies Inc. | 1 | $30 |
| Endo USA, Inc. | 1 | $26 |
| Halozyme Inc | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,144 in reported general payments places this provider in the 95th percentile of 457 medical providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 40 | $151,607 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 26 | $122,209 |
| DescovyEmtricitabine/Tenofov Alafenam | 40 | $85,099 |
| DovatoDolutegravir Sodium/Lamivudine | 26 | $76,294 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $62,557 |
| TivicayDolutegravir Sodium | 25 | $55,726 |
| Maraviroc | 26 | $53,654 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $52,024 |
| IsentressRaltegravir Potassium | 26 | $49,895 |
| JulucaDolutegravir/Rilpivirine | 12 | $40,591 |
| PrezcobixDarunavir/Cobicistat | 11 | $26,052 |
| Etravirine | 26 | $22,840 |
| Darunavir | 13 | $20,596 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 25 | $16,541 |
| VemlidyTenofovir Alafenamide | 11 | $15,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy, Biktarvy, Genvoya, Vemlidy | $7,055 | $214,94879 claims |
| Viiv Healthcare CompanyDovato, Tivicay, Juluca | $2,581 | $172,61263 claims |
| MerckIsentress, Belsomra | $180 | $56,13640 claims |
| Johnson & JohnsonPrezcobix | $484 | $26,05211 claims |
| PfizerEliquis | $329 | $6,87613 claims |
| GSKArnuity Ellipta | $117 | $2,46213 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $12 | $36059 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 medical providers in Washington.
Other medical in Seattle
- Diana McFarlaneSeattle$95K
- Amy NelsonSeattle$15K
- Kenya KiddSeattle$7K
- Sarith KeoSeattle$5K
- Rebecca PattonSeattle$5K
- Lindsey MillsSeattle$4K
- Karissa SecoraTacoma$53K
- Tori FranklinLakewood$23K
- Salvador LopezYakima$17K
- Rebecca JohnsonSpokane$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.